Sanofi Aventis Pharmaceutical Import Profile — France (DGFT 2022–2026)

Name: Sanofi Aventis Pharmaceutical Import Records from India — 2 Products, $6.8M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Sanofi Aventis — Pharmaceutical Importer Profile (2026) | 2 Products, $6.8M Trade | TransData Nexus

Sanofi Aventis

Pharmaceutical Importer · France · Antibiotics Focus · $6.8M Total Trade · DGFT Verified

Sanofi Aventis is a pharmaceutical importer based in France with a total trade value of $6.8M across 2 products in 2 therapeutic categories. Based on 223 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Sanofi Aventis sources from 5 verified Indian suppliers, with Medreich Limited accounting for 73.6% of imports.

Sanofi Aventis — Import Portfolio & Supplier Network

Sanofi Aventis import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Sanofi Aventis?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Medreich Limited	$13.7M	569	73.6%
Sanofi India Limited	$3.5M	87	18.6%
Cipla Limited	$715.9K	48

What Formulations Does Sanofi Aventis Import?

Formulation	Value	Ships
Amoxicillin and potassium	$1.0M	28
Paracetamol 325MG,ibuprofen 200MG and	$804.9K	19
Paracetamol 325MG ,ibuprofen 200MG and	$590.6K	15
Amoxicillin and potassium clavulanate	$479.9K	20
Tamsulosin 0.4MG pellets (tamsulosin	$449.9K	9
Amoxicillin and potassium clavulanate	$398.2K	11
Amoxicillin and potassium clavulanate	$264.4K	6
Amoxicillin 1g and clavulanic acid 125	$259.5K	6
Pharmaceutical products-trental 400MG	$257.4K	6
Amoxicillin 500MG capsules (amitron)	$237.8K	7
Amoxicillin 1g and clavulanic acid 125MG	$226.1K	7
Amoxicillin 1g and clavulanic acid	$219.1K	6
Amoxicillin and pottassium	$189.1K	6
Amoxicillin oral suspension BP 250MG/5ML	$186.5K	12
Amoxicillin and clavulanate potassium	$181.5K	8

Sanofi Aventis imports 351 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Amoxicillin	Antibiotics	$5.6M	168	0.9%	15
2	Caffeine	Respiratory & OTC	$1.3M	55	1.2%	9

Sanofi Aventis imports 2 pharmaceutical products across 2 categories into France totaling $6.8M.

Sanofi Aventis — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Sanofi Aventis, now known as Sanofi, is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. Established in 1973 as a subsidiary of the French petrochemical firm Elf Aquitaine, Sanofi has evolved into one of the world's leading pharmaceutical companies. In 1999, Sanofi merged with Synthélabo, a subsidiary of L'Oréal, forming Sanofi-Synthélabo. The company further expanded in 2004 by acquiring Aventis, a merger between Rhône-Poulenc and Hoechst Marion Roussel, resulting in the formation of Sanofi-Aventis. In May 2011, the company rebranded to Sanofi.

Sanofi specializes in the research, development, manufacturing, and marketing of pharmaceutical products, including prescription medications, over-the-counter drugs, vaccines, and diagnostics. The company operates across seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines. Sanofi Pasteur, a subsidiary of Sanofi, is the world's largest producer of vaccines.

2Distribution Network

Sanofi's distribution network in France is extensive, with multiple warehouses and logistics centers strategically located to ensure efficient delivery of pharmaceutical products nationwide. The company has invested significantly in its French operations, including a €1.1 billion investment announced in May 2024 for the construction of a new facility in Vitry-sur-Seine, dedicated to monoclonal antibody production. This facility is expected to double the site's production capacity and create 350 jobs. (lemonde.fr)

Additionally, Sanofi has committed to modernizing and expanding its production capabilities in France. In November 2024, the company announced a €40 million investment in its Gerland site in Lyon, marking 40 years of its presence in the region. This investment will fund two new bioproduction platforms: one to increase the production capacity of Thymoglobuline, used to prevent organ transplant rejection, and another to produce a new monoclonal antibody for the treatment of type 1 diabetes. (lemonde.fr)

3Industry Role

Sanofi plays a pivotal role in France's pharmaceutical supply chain, primarily acting as a wholesaler and distributor. The company's extensive distribution network ensures the efficient delivery of a wide range of pharmaceutical products to various stakeholders, including hospitals, pharmacies, and healthcare providers. Sanofi's significant investments in French manufacturing facilities underscore its commitment to maintaining a robust and resilient supply chain within the country. (lemonde.fr)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Sanofi Aventis

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Sanofi's sourcing strategy from India reveals a high degree of concentration, with a total import value of $6.8 million USD across 223 shipments, primarily consisting of two products: Amoxicillin and Caffeine. This concentration indicates a strategic choice to focus on specific products, potentially leveraging cost advantages and supplier expertise. The dominance of these two products in Sanofi's Indian imports suggests a stable and long-term relationship with its Indian suppliers, as evidenced by the substantial import values and consistent shipment volumes.

The primary supplier, MEDREICH LIMITED, accounts for 73.6% of the total import value, indicating a strong and possibly exclusive partnership. The second-largest supplier, SANOFI INDIA LIMITED, contributes 18.6% to the total import value, suggesting a strategic alignment with Sanofi's global operations. The remaining suppliers, including CIPLA LIMITED, ZENTIVA PRIVATE LIMITED, and SANOFI HEALTHCARE INDIA PRIVATE LIMITED, collectively account for a smaller portion of the imports, indicating a diversified yet concentrated sourcing approach.

2Supply Chain Resilience

Sanofi's supply chain resilience concerning Indian imports appears robust, given the concentration on two primary products and a limited number of suppliers. The substantial import values and consistent shipment volumes from MEDREICH LIMITED and SANOFI INDIA LIMITED suggest a stable and reliable supply chain. However, the high concentration on these two products may pose risks if there are disruptions in supply or regulatory changes affecting these specific formulations.

Importing Pharmaceuticals into France — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for France

1Regulatory Authority & Framework

In France, the primary regulatory authority overseeing pharmaceutical imports is the French National Agency for Medicines and Health Products Safety (ANSM). ANSM is responsible for ensuring the safety, efficacy, and quality of health products, including pharmaceuticals, medical devices, and cosmetics. The agency establishes guidelines and regulations for the importation, distribution, and marketing of pharmaceutical products within France.

Key legislation governing pharmaceutical imports into France includes the Public Health Code (Code de la santé publique), which outlines the requirements for marketing authorization, importation procedures, and the responsibilities of stakeholders in the pharmaceutical supply chain. Additionally, France adheres to European Union regulations concerning pharmaceutical imports, ensuring compliance with EU-wide standards for product quality, safety, and efficacy.

The marketing authorization pathway for Indian generics involves obtaining approval from ANSM, which includes submitting a dossier demonstrating the product's bioequivalence to the reference product, compliance with Good Manufacturing Practice (GMP) standards, and adherence to labeling and packaging requirements. Collaboration with the European Medicines Agency (EMA) may also be necessary for certain products, especially those intended for broader EU distribution.

2Import Licensing & GMP

Sanofi Aventis — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Sanofi's product strategy focuses on key therapeutic areas, including cardiovascular, central nervous system, oncology, and internal medicine. Flagship products such as Allegra® (allergy), Lovenox® (deep vein thrombosis), Plavix® (thrombosis), Avapro® (hypertension), Ambien® (ins

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — Sanofi Aventis

What products does Sanofi Aventis import from India?

Sanofi Aventis imports 2 pharmaceutical products across 2 categories. Top imports: Amoxicillin ($5.6M), Caffeine ($1.3M).

Who supplies pharmaceuticals to Sanofi Aventis from India?

Sanofi Aventis sources from 5 verified Indian suppliers. The primary supplier is Medreich Limited (73.6% of imports, $13.7M).

What is Sanofi Aventis's total pharmaceutical import value?

Sanofi Aventis's total pharmaceutical import value from India is $6.8M, based on 223 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Sanofi Aventis focus on?

Sanofi Aventis imports across 2 categories. The largest: Antibiotics (81.2%), Respiratory & OTC (18.8%).

Get Full Sanofi Aventis Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.